NCT06305663View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

NARecruitingINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Myopia
Interventions
DEVICE

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

DEVICE

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Trial Locations (11)

100044

ACTIVE_NOT_RECRUITING

Site 105, Beijing

100730

ACTIVE_NOT_RECRUITING

Site 107, Dongcheng

200433

ACTIVE_NOT_RECRUITING

Site 102, Shanghai

300392

ACTIVE_NOT_RECRUITING

Site 104, Nankai

325027

RECRUITING

Site 101, Wenzhou

361004

ACTIVE_NOT_RECRUITING

Site 109, Xiamen

430012

ACTIVE_NOT_RECRUITING

Site 110, Wuhan

518040

ACTIVE_NOT_RECRUITING

Site 108, Shenzhen

570311

ACTIVE_NOT_RECRUITING

Site 111, Haikou

610044

ACTIVE_NOT_RECRUITING

Site 103, Chengdu

030072

ACTIVE_NOT_RECRUITING

Site 106, Taiyuan

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY